Cocaine Dependence
Conditions
Keywords
cocaine dependence, levodopa, carbidopa, entacapone
Brief summary
The proposed study will look at cocaine dependent individuals and will consist of three consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient phase (during which participants will start study medication of levodopa,carbidopa and entacapone (LCE) and will undergo brain imaging and 3) the 24 weeks outpatient treatment trial. The purpose is to see if treatment with LCE may reverse baseline brain deficits and if this change is associated with clinical improvement. Hypothesis is that treatment with LCE, compared to placebo, increases abstinence from cocaine over a 12-week trial in combination with behavioral treatment with voucher incentives.
Detailed description
Cocaine dependence remains a serious public health problem; however no clearly effective pharmacological treatments have been identified to date. The investigators hypothesize that identification of subgroups of cocaine-dependent patients will help to develop targeted and more effective treatments. The investigators have observed that 30-40% of cocaine-dependent patients who enter our medication trials achieve abstinence during the lead-in period (the two weeks prior to starting medication). Initial abstinence is strongly predictive of abstinence during the subsequent medication trial. The investigators have also observed that a low dopamine release in the striatum is associated with greater choice of cocaine in volunteers and failure of cocaine-dependent patients to respond to behavioral treatment. The investigators hypothesize that individuals who have difficulties in achieving abstinence have a deficit in dopaminergic functioning and correcting this deficit using dopaminergic medication LCE (levodopa in combination with carbidopa and entacapone) will result in clinical improvement. The proposed study will consist of three consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient phase (during which participants will start study medication and will undergo brain imaging; one PET and two fMRI scan sessions); and 3) the 24 weeks outpatient treatment trial. Study medication (LCE or placebo) will be administered in a double-blind, placebo controlled manner for one week during inpatient phase followed by 12 weeks of the outpatient trial. During the remaining 12 weeks of the outpatient trial participants will receive therapy only. The purpose of the lead-in phase is to identify patients who do not achieve abstinence in response to behavioral treatment. Subsequently, two matched subgroups of participants (half who achieved abstinence and half who did not achieve abstinence) will undergo the \[11C\] raclopride displacement PET brain imaging procedure. This procedure allows the measurement of dopamine release in response to a single dose of methylphenidate, and the investigators will determine if failure to achieve abstinence during the lead-in period is associated low dopamine transmission. All participants in the proposed study will also undergo a functional MRI with the Motivational Incentive Delay task (fMRI/MID). This task is thought to reflect dopaminergic transmission in the brain-reward system but is safer and more feasible than PET. The investigators hypothesize that fMRI/MID will correlate strongly with results from the PET procedure, thereby suggesting that it also reflects the status of striatal dopamine functioning. In addition, a group of healthy controls will undergo one fMRI scan in order to validate the procedure and to assess if a deficit can be detected in cocaine-dependent participants. Cocaine-dependent participants will undergo two fMRI/MID, one at baseline and another after a week of treatment with LCE to assess if treatment with LCE may reverse baseline deficits and if this change is associated with clinical improvement.
Interventions
DRUGlevodopa carbidopa and entacapone (LCE)
400mg/100mg/200mg, twice daily
DRUGPlacebo
matched placebo for LCE condition dosed twice daily
Sponsors
New York State Psychiatric Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult, age 21-50. * Meets DSM-IV criteria for current cocaine dependence, supported by a positive urine for cocaine metabolites * Voluntarily seeking treatment for cocaine dependence * Absence of other medical or psychiatric disorders that are unstable and would interfere with participation. * Absence of any suspicious skin changes, suggestive of melanoma, during the full body exam * Able to give informed consent.
Exclusion criteria
* Current DSM-IV criteria of other substance use disorders with the exception of nicotine dependence, and mild to moderate alcohol or cannabis abuse or dependence. Alcohol or cannabis abuse or dependence may be included provided that cocaine is the predominant problem, and medical detoxification is not indicated; alcohol and cannabis use are common among cocaine dependent patients and their categorical exclusion would impede recruitment and result in a sample of limited generalizability; secondary analyses will explore whether they exert any moderating effects on the main findings. * Active psychiatric disorder which might interfere with participation or make participation hazardous, including DSM-IV organic mental disorder, psychotic disorder, bipolar disorder, recurrent severe MDD, OCD, or eating disorder. Participants with depressive disorder (provided that the score on the Hamilton Depression Scale is less than 20) and those with ADHD symptoms may be included, since these are common, often reflect effects of chronic drug use, and may improve with behavioral treatment and cessation or reduction of drug use. * Unstable medical disorders, or medical disorders that might interfere with study participation, including seizure disorder. * Significant current suicidal risk or 1 or more suicide attempts within the past year * Concurrent treatment with psychotropic medications * Positive serum pregnancy test, lactation, or unwillingness to use a satisfactory method of birth control * Baseline systolic BP of \> 140 and \< 100, diastolic BP \> 90 and \< 60 and baseline HR greater than 90. * Any clinically significant heart abnormality or cardiovascular disease * History of glaucoma * History of melanoma or current suspicious undiagnosed skin lesions * History of allergic reaction or adverse reaction to study medications (levodopa/carbidopa/entacapone; methylphenidate; raclopride). * Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan as determined in consultation with a neuroradiologist and according to the guidelines set forth in the following reference book commonly used by neuroradiologists: Guide to MR procedures and metallic objects by Shellock * Lifetime exposure to radiation in the workplace, or history of participation in nuclear medicine procedures, including research protocols * Individuals who are predominantly left handed. Based on a score \<50 on the Edinburg Handed Inventory (E.H.I.). Inclusion Criteria(fMRI study-healthy controls): * Adult, age 21-50. * No current DSM-IV psychiatric or substance use disorders * Absence of other medical disorders that are unstable and would interfere with participation. * Able to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cocaine Urine Toxicology | collected 3x/week for 24 weeks of trial or for the duration of the participants involvement in the study. | Abstinence will be assessed by urine toxicology results collected 3x/week during the 24 week trial or for the length of participation |
| Retention in Treatment | 12 weeks | The number of participants who completed the 12-week medication phase of the study. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Levodopa Carbidopa and Entacapone (LCE) 400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
levodopa carbidopa and entacapone (LCE): 400mg/100mg/200mg, twice daily | 9 |
| Placebo placebo
Placebo: matched placebo for LCE condition dosed twice daily | 10 |
| Non-randomized | 4 |
| Total | 23 |
Baseline characteristics
| Characteristic | Levodopa Carbidopa and Entacapone (LCE) | Placebo | Non-randomized | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants | 10 Participants | 4 Participants | 23 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 10 Participants | 4 Participants | 20 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Male | 7 Participants | 10 Participants | 4 Participants | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 3 / 9 | 5 / 10 | 0 / 4 |
| serious Total, serious adverse events | 1 / 9 | 1 / 10 | 0 / 4 |
Outcome results
Primary
Cocaine Urine Toxicology
Abstinence will be assessed by urine toxicology results collected 3x/week during the 24 week trial or for the length of participation
Time frame: collected 3x/week for 24 weeks of trial or for the duration of the participants involvement in the study.
Population: Urine toxicology results were not collected
Primary
Retention in Treatment
The number of participants who completed the 12-week medication phase of the study.
Time frame: 12 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levodopa Carbidopa and Entacapone (LCE) | Retention in Treatment | 7 participants |
| Placebo | Retention in Treatment | 9 participants |
| Non-randomized | Retention in Treatment | 0 participants |